BioCryst Pharmaceuticals | BCRX - Loan Capital

Stock Price
9.48
Daily Change
-0.19 -1.92%
Monthly
19.94%
Yearly
21.47%
Q1 Forecast
9.41

BioCryst Pharmaceuticals reported $428.67M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
Chugai Pharma JPY 4.53B 1.95B Dec/2024
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
DBV Technologies USD 0 0 Mar/2025
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Glaxosmithkline GBP 19.82B 203.13M Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Karyopharm Therapeutics USD -0.93 0.67 Dec/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novavax USD 246.3M 200K Dec/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025